Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Kirkstall is a private UK biotechnology and life science tools company focused on organ-on-a-chip and interconnected cell-culture systems for more human-relevant research. Its core commercial platform, Quasi Vivo®, is a dynamic flow-based in vitro system used by academic and pharmaceutical laboratories to model organ interactions, study disease biology, and assess drug toxicity under more physiologic conditions. The company positions its technology as an animal-replacement or animal-reduction research tool intended to improve translational relevance versus conventional static cell culture and some animal models. Kirkstall appears to operate primarily as a platform and products company rather than a therapeutics developer, with commercial offerings including Quasi Vivo instrument systems and related accessories. Its collaborations and application base span multiple university and industry laboratories, particularly in organ-on-chip and microphysiological systems research.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Kirkstall.